Effect of a monoclonal antibody to PCSK9 on LDL cholesterol [2]

New England Journal of Medicine

Volumn 366, Issue 25, 2012, Pages 2425-2426

  Banerjee, Yajnavalka ^a   Shah, Karna ^a   Al Rasadi, Khalid ^a  

^a SULTAN QABOOS UNIVERSITY   (Oman)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; REGN 727; SERINE PROTEINASE; UNCLASSIFIED DRUG; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN RECEPTOR;

BINDING AFFINITY; CHRONIC DRUG ADMINISTRATION; DRUG EFFECT; FAMILIAL HYPERCHOLESTEROLEMIA; GAIN OF FUNCTION MUTATION; HUMAN; LETTER; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR BINDING; BLOOD; DRUG ANTAGONISM; FEMALE; HYPERCHOLESTEROLEMIA; MALE; NOTE;

ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; PROPROTEIN CONVERTASES; RECEPTORS, LDL;

EID: 84862564591     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1204929     Document Type: Letter

References (3)

1. Abifadel M, Rabès JP, Devillers M, et al. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat 2009;30:520-9.
2. Duff CJ, Scott MJ, Kirby IT, Hutchinson SE, Martin SL, Hooper NM. Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem J 2009;419:577-84.
3. Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A 2003;100:928-33. (Pubitemid 36183932)